This is a non-binding, exploratory collaboration with no financial terms disclosed — treat as a low-impact narrative event. Monitor for any subsequent 6-K or 8-K that provides concrete investment size or development milestones.
Price Chart
Executive Summary
Trinity Biotech announced a strategic collaboration and planned equity investment in Latch Medical to combine its CGM+ wearable biosensor platform with Latch Medical's intradermal drug delivery technology for metabolic health solutions. The deal is exploratory and non-binding (investment agreed 'in principle'), with no disclosed financial terms. Perceptive Advisors, Trinity's largest investor, is supporting the investment. This is a forward-looking pipeline expansion story with no near-term revenue impact, typical for a micro-cap diagnostics company.
Key Facts
- Trinity Biotech partnered with Latch Medical to explore biosensor-guided precision drug delivery using CGM+ technology.
- Trinity agreed in principle to make a strategic equity investment in Latch Medical; amount undisclosed.
- Perceptive Advisors, Trinity's largest financial investor, is supporting the equity investment.
- The collaboration targets diabetes, obesity, and other metabolic conditions but is exploratory with no product or revenue timeline.
- Latch Medical's Pharma Latch platform is pre-approval and not for sale in any jurisdiction.
Financial Impact
Undisclosed equity investment amount; no revenue or cost figures provided.
Risk Factors
- No disclosed investment amount or binding commitment — deal may not materialize.
- Latch Medical's Pharma Latch platform is pre-approval and not yet commercialized anywhere.
- Trinity Biotech has a $7M market cap and faces Nasdaq continued listing risk per its own risk factors.
- Forward-looking statements only; no near-term revenue or product launch timeline.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001554855-26-001608 |
| Document: MainDocument.htm | 0001554855-26-001608 |
| Document: 0001554855-26-001608-index-headers.html | 0001554855-26-001608 |
| Document: 0001554855-26-001608-index.html | 0001554855-26-001608 |
| Document: 0001554855-26-001608.txt | 0001554855-26-001608 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 6-K | $5.77 | awaiting T+60 | — | $7.11 (+23.22%) |
Sep 9, 2026 6w ago | 6-K | $8.00 | awaiting T+60 | — | $7.11 (−11.12%) |
Sep 2, 2026 7w ago | EFFECT | $9.60 | awaiting T+60 | — | $7.11 (−25.94%) |
Aug 28, 2026 8w ago | 6-K | $9.87 | awaiting T+60 | — | $7.11 (+27.96%) |
Aug 21, 2026 9w ago | F-1/A | $10.60 | awaiting T+60 | — | $7.11 (−32.92%) |
Aug 17, 2026 10w ago | 6-K | $11.17 | awaiting T+60 | — | $7.11 (−36.35%) |
Aug 14, 2026 10w ago | 6-K | $11.67 | awaiting T+60 | — | $7.11 (−39.07%) |
Jul 22, 2026 13w ago | 6-K | $0.3033 $0.2643 | ▼ −12.85% | ▼ −16.11% | $7.11 (+2244.21%) |
Jul 22, 2026 13w ago | 6-K | $0.3033 $0.2643 | ▼ −12.85% | ▼ −16.11% | $7.11 (+2244.21%) |
Jul 2, 2026 16w ago | 6-K | $0.3765 $0.2240 | ▼ −40.50% | ▼ −43.30% | $7.11 (+1788.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers